Have a feature idea you'd love to see implemented?
Let us know!
ALT Altimmune Inc
Price (delayed)
$8.25
Market cap
$586.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.57
Enterprise value
$555.26M
Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Its diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™),
Highlights
ALT's quick ratio is up by 48% QoQ and by 36% YoY
Altimmune's EPS has increased by 4.3% QoQ
ALT's revenue has dropped by 87% since the previous quarter and by 81% year-on-year
The gross profit has plunged by 87% from the previous quarter and by 81% YoY
Key stats
What are the main financial stats of ALT
Market
Valuations
Earnings
Shares outstanding
71.12M
Market cap
$586.78M
Enterprise value
$555.26M
Price to earnings (P/E)
N/A
Price to book (P/B)
4.4
Price to sales (P/S)
11,277.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,678.12
Revenue
$52,000
Gross profit
$52,000
Net income
-$103.52M
EBIT
-$103.51M
EBITDA
-$101.42M
Free cash flow
-$78.12M
Per share
Balance sheet
Liquidity
EPS
-$1.57
EPS diluted
-$1.57
Free cash flow per share
-$1.1
Book value per share
$1.88
Revenue per share
$0
TBVPS
$2.08
Total assets
$147.86M
Total liabilities
$14.49M
Debt
$0
Equity
$133.38M
Working capital
$137.12M
Debt to equity
0
Current ratio
16.87
Quick ratio
16.19
Net debt/EBITDA
0.31
Margins
Efficiency
Dividend
EBITDA margin
-195,028.8%
Gross margin
100%
Net margin
-199,076.9%
Operating margin
-215,248.1%
Return on assets
-57.5%
Return on equity
-63.4%
Return on invested capital
-111.9%
Return on capital employed
-74.3%
Return on sales
-199,057.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALT stock price
How has the Altimmune stock price performed over time
Intraday
0.86%
1 week
-8.64%
1 month
2.48%
1 year
3.38%
YTD
-26.67%
QTD
34.36%
Financial performance
How have Altimmune's revenue and profit performed over time
Revenue
$52,000
Gross profit
$52,000
Operating income
-$111.93M
Net income
-$103.52M
Gross margin
100%
Net margin
-199,076.9%
ALT's revenue has dropped by 87% since the previous quarter and by 81% year-on-year
The gross profit has plunged by 87% from the previous quarter and by 81% YoY
Altimmune's net income has decreased by 32% YoY and by 2.1% QoQ
Altimmune's operating income has decreased by 31% YoY and by 2% from the previous quarter
Growth
What is Altimmune's growth rate over time
Valuation
What is Altimmune stock price valuation
P/E
N/A
P/B
4.4
P/S
11,277.87
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
10,678.12
Altimmune's EPS has increased by 4.3% QoQ
The P/B is 100% higher than the 5-year quarterly average of 2.2 and 29% higher than the last 4 quarters average of 3.4
The equity has declined by 13% since the previous quarter and by 11% year-on-year
ALT's revenue has dropped by 87% since the previous quarter and by 81% year-on-year
Efficiency
How efficient is Altimmune business performance
ALT's ROA is down by 36% YoY and by 4.7% QoQ
The return on equity has declined by 35% year-on-year and by 4.8% since the previous quarter
The company's return on invested capital rose by 17% YoY and by 12% QoQ
Dividends
What is ALT's dividend history
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
Dividend history
Special dividends are included in TTM DPS and yield
Financial health
How did Altimmune financials performed over time
Altimmune's current ratio has increased by 49% from the previous quarter and by 31% YoY
ALT's quick ratio is up by 48% QoQ and by 36% YoY
The debt is 100% smaller than the equity
The equity has declined by 13% since the previous quarter and by 11% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.